Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 176

Sort by

Sort Order Select

Journal Articles

Cerebrospinal fluid distribution and pharmacokinetics of ponatinib in Ph1 + acute lymphoblastic leukemia

Pierre Walczak, Sofiane Fodil, Nicolas Vignal, Aurélie Cabannes-Hamy, Nicolas Boissel, Emmanuel Raffoux, Jean-Michel Cayuela, Lauriane Goldwirt, Etienne Lengliné

Blood (2024) 144 (10): 1127–1130.

https://doi.org/10.1182/blood.2024024838

Published: 2024

Journal Articles

Nilotinib with or without cytarabine for Philadelphia-positive acute lymphoblastic leukemia

Blood (2024) 143 (23): 2363–2372.

https://doi.org/10.1182/blood.2023023502

Published: 2024

Includes: Supplemental data

Journal Articles

Genetic alterations and MRD refine risk assessment for KMT2A -rearranged B-cell precursor ALL in adults: a GRAALL study

Blood (2023) 142 (21): 1806–1817.

https://doi.org/10.1182/blood.2023021501

Published: 2023

Includes: Supplemental data

Journal Articles

Long-Term Real-World Experience of CPX-351 in Combined French-Italian Cohorts Identified High Rate of Negative Measurable Residual Disease (MRD) and Prolonged Overall Survival

Blood (2023) 142 (Supplement 1): 4255.

https://doi.org/10.1182/blood-2023-177951

Published: 2023

Journal Articles

Venetoclax in Combination with Intermediate Doses of Cytarabine in Consolidation Phase for Acute Myeloid Leukemia Patients in First Complete Remission; Results of the Part 1 of the Phase 1/2 Multicentric Covenidac Study

Blood (2023) 142 (Supplement 1): 4261.

https://doi.org/10.1182/blood-2023-173656

Published: 2023

Journal Articles

The Splicing-Associated Network PAK1-Clk-SRRM1 Is a Critical Vulnerability to Overcome Chemoresistance in Acute Myeloid Leukemia

Blood (2023) 142 (Supplement 1): 409.

https://doi.org/10.1182/blood-2023-186264

Published: 2023

Journal Articles

Current Results of Intensive Therapy in Younger Adults with Acute Myeloid Leukemia (AML): The Large Randomized French Backbone Intergroup (BIG)-1 Study on Behalf of the Filo, ALFA, and SFGM-TC Study Groups

Blood (2023) 142 (Supplement 1): 967.

https://doi.org/10.1182/blood-2023-179376

Published: 2023

Journal Articles

Gemtuzumab Ozogamicin for Patients with Newly Diagnosed CD33 Positive Acute Myeloid Leukemia: Results from a French Retrospective Observational Study

Juliette Lambert, Emmanuel Raffoux, Delphine Lebon, Thorsten Braun, Mael Heiblig, Alberto Santagostino, Karin Gogat-Marchant, Cécile Pautas

Blood (2023) 142 (Supplement 1): 2893.

https://doi.org/10.1182/blood-2023-179575

Published: 2023

Journal Articles

Impact of Arsenic Trioxide in the Treatment of Higher Risk Acute Promyelocytic Leukemia

Blood (2023) 142 (Supplement 1): 1471.

https://doi.org/10.1182/blood-2023-174446

Published: 2023

Journal Articles

In silico and Functional Studies for Classification of EPAS1/HIF2A Genetic Variants Identified in Patients with Erythrocytosis

Valéna Karaghiannis, Darko Maric, Céline Garrec, Nada Maaziz, Alexandre Buffet, Vincent Antunes, Amandine le Roy, Fabrice Airaud, Bernard Aral, Loic Schmitt, Sébastien Corbineau, Lamisse Mansour-Hendili, Valentine Lesieur, Antoine Rimbert, Fabien Laporte, Marine Delamare, Stephane Bezieau, Bruno Cassinat, Frédéric Galactéros, Anne-Paule Gimenez-Roqueplo, Nelly Burnichon, Holger Cario, Richard van Wijk, Celeste Bento, Anaise Blouet, Juliette Bouteloup, Françoise Boyer perrard, Aisha Aiko Bruce, Emilie Cayssials, Nicole Casadevall, Brieuc Cherel, Marielaure Couec, Louis Drevon, Cecile Dumesnil, Thierry Lamy De La Chapelle, Marion Gambart, Loic Garcon, Brigitte Granel, Pierre Hirsch, Agnès Lahary, Amira Mejri, Sandrine Meunier, Franck E. Nicolini, Emmanuel Raffoux, Dana Ranta, Nicolas Schleinitz, Jean Baptiste Valentin, Mathieu Wemeau, Francois Girodon, David Hoogewijs, Betty Gardie, Olivier Hermine

Blood (2022) 140 (Supplement 1): 8157–8158.

https://doi.org/10.1182/blood-2022-163123

Published: 2022

Journal Articles

Gilteritinib Activity in Refractory or Relapsed FLT3 -Mutated Acute Myeloid Leukemia Patients Previously Treated By Intensive Chemotherapy and Midostaurin: A Study from the French AML Intergroup ALFA/Filo

Blood (2022) 140 (Supplement 1): 8996–8998.

https://doi.org/10.1182/blood-2022-159125

Published: 2022

Journal Articles

Distinct Clinico-Molecular Arterial and Venous Thrombotic Scoring Systems for MPN Patients Risk Stratification

Hélène Pasquer, Rafael Daltro De Oliveira, Juliette Soret, Nabih Maslah, Lin-Pierre Zhao, Clemence Marcault, Marine Cazaux, Nicolas Gauthier, Emmanuelle Verger, Nathalie Parquet, William Vainchenker, Emmanuel Raffoux, Stephane Giraudier, Bruno Cassinat, Jean-Jacques Kiladjian, Lina Benajiba

Blood (2022) 140 (Supplement 1): 830–831.

https://doi.org/10.1182/blood-2022-160329

Published: 2022

Journal Articles

Characteristics of Germline CHEK2 Mutated Patients in a Large Cohort of 2322 Myeloid Malignancies

Lucie Freiman, Lise Larcher, Giulia Tueur, Nadia Vasquez, Mélanie Da Costa, Emmanuel Raffoux, Lionel Ades, Pierre Fenaux, Jean Soulier, Emmanuelle Clappier, Raphael Itzykson

Blood (2022) 140 (Supplement 1): 4082–4083.

https://doi.org/10.1182/blood-2022-158799

Published: 2022

Journal Articles

Fractionated Inotuzumab Ozogamicin Combined with Low-Intensity Chemotherapy in Older Patients with Newly Diagnosed CD22+ Philadelphia Chromosome (Ph)-Negative B-Cell Precursor (BCP) Acute Lymphoblastic Leukemia (ALL): Results of the EWALL-INO Study

Patrice Chevallier, Thibault Leguay, Rathana KIM, Marc Delord, Michael Doubek, Francoise Huguet, Aurelie Cabannes-Hamy, Ulla Wartiovaara-Kautto, Colombe Saillard, Emmanuel Raffoux, Thomas Cluzeau, Stephane Lepretre, Marie Balsat, Anna Berceanu, Nicolas Boissel, Claude Gardin, Emmanuelle Clappier, Herve Dombret, Philippe Rousselot

Blood (2022) 140 (Supplement 1): 6114–6116.

https://doi.org/10.1182/blood-2022-166035

Published: 2022

Journal Articles

JAK Inhibition Mediates Clonal Selection of RAS Pathway Mutations in Myeloproliferative Neoplasms

Blood (2022) 140 (Supplement 1): 795–796.

https://doi.org/10.1182/blood-2022-167719

Published: 2022

Journal Articles

Impact of NFE2 mutations on AML transformation and overall survival in patients with myeloproliferative neoplasms

Blood (2021) 138 (21): 2142–2148.

https://doi.org/10.1182/blood.2020010402

Published: 2021

Includes: Supplemental data

Journal Articles

Genomic Landscape and Clinical Features of Myeloproliferative Neoplasm (MPN) Patients with Auto-Immune and Inflammatory Diseases (AID)

Dikelele Elessa, Lin-Pierre Zhao, Rafael Daltro De Oliveira, Nabih Maslah, Juliette Soret-Dulphy, Emmanuelle Verger, Clemence Marcault, Nathalie Parquet, Pierre Fenaux, Lionel Ades, Emmanuel Raffoux, Stephane Giraudier, Olivier Fain, Bruno Cassinat, Jean-Jacques Kiladjian, Arsene Mekinian, Lina Benajiba

Blood (2021) 138 (Supplement 1): 1496.

https://doi.org/10.1182/blood-2021-152302

Published: 2021

Journal Articles

Retrospective Analysis of the Outcomes of Patients with Relapsed/Refractory Acute Myeloid Leukemia Included in a Patient Named Program of Gemtuzumab Ozogamicin

Blood (2021) 138 (Supplement 1): 876.

https://doi.org/10.1182/blood-2021-145184

Published: 2021

Journal Articles

The Omission of High-Dose Cytarabine during Consolidation Therapy of Ph-Positive ALL Patients Treated with Nilotinib and Low-Intensity Chemotherapy Results in an Increased Risk of Relapses Despite Non-Inferior Levels of Late BCR-ABL1 MRD Response. First Results of the Randomized Graaph-2014 Study

Blood (2021) 138 (Supplement 1): 512.

https://doi.org/10.1182/blood-2021-148843

Published: 2021

Journal Articles

Fractionated Inotuzumab Ozogamicin Combined with Low-Intensity Chemotherapy Provides Very Good Outcome in Older Patients with Newly Diagnosed CD22+ Philadelphia Chromosome-Negative B-Cell Precursor Acute Lymphoblastic Leukemia: First Results from the EWALL-INO Study

Patrice Chevallier, Thibault Leguay, Michael Doubek, Francoise Huguet, Cyril Salek, Aurélie Cabannes, Ulla Wartiovaara-Kautto, Colombe Saillard, Emmanuel Raffoux, Thomas Cluzeau, Stéphane Leprêtre, Marie Balsat, Anna Berceanu, Nicolas Boissel, Emmanuelle Clappier, Laure Morisset, Claude Gardin, Hervé Dombret, Philippe Rousselot

Blood (2021) 138 (Supplement 1): 511.

https://doi.org/10.1182/blood-2021-148625

Published: 2021

NARROW

Cerebrospinal fluid distribution and pharmacokinetics of ponatinib in Ph1 + acute lymphoblastic leukemia

Nilotinib with or without cytarabine for Philadelphia-positive acute lymphoblastic leukemia

Genetic alterations and MRD refine risk assessment for KMT2A -rearranged B-cell precursor ALL in adults: a GRAALL study

Long-Term Real-World Experience of CPX-351 in Combined French-Italian Cohorts Identified High Rate of Negative Measurable Residual Disease (MRD) and Prolonged Overall Survival

Venetoclax in Combination with Intermediate Doses of Cytarabine in Consolidation Phase for Acute Myeloid Leukemia Patients in First Complete Remission; Results of the Part 1 of the Phase 1/2 Multicentric Covenidac Study

The Splicing-Associated Network PAK1-Clk-SRRM1 Is a Critical Vulnerability to Overcome Chemoresistance in Acute Myeloid Leukemia

Current Results of Intensive Therapy in Younger Adults with Acute Myeloid Leukemia (AML): The Large Randomized French Backbone Intergroup (BIG)-1 Study on Behalf of the Filo, ALFA, and SFGM-TC Study Groups

Gemtuzumab Ozogamicin for Patients with Newly Diagnosed CD33 Positive Acute Myeloid Leukemia: Results from a French Retrospective Observational Study

Impact of Arsenic Trioxide in the Treatment of Higher Risk Acute Promyelocytic Leukemia

In silico and Functional Studies for Classification of EPAS1/HIF2A Genetic Variants Identified in Patients with Erythrocytosis

Gilteritinib Activity in Refractory or Relapsed FLT3 -Mutated Acute Myeloid Leukemia Patients Previously Treated By Intensive Chemotherapy and Midostaurin: A Study from the French AML Intergroup ALFA/Filo

Distinct Clinico-Molecular Arterial and Venous Thrombotic Scoring Systems for MPN Patients Risk Stratification

Characteristics of Germline CHEK2 Mutated Patients in a Large Cohort of 2322 Myeloid Malignancies

Fractionated Inotuzumab Ozogamicin Combined with Low-Intensity Chemotherapy in Older Patients with Newly Diagnosed CD22+ Philadelphia Chromosome (Ph)-Negative B-Cell Precursor (BCP) Acute Lymphoblastic Leukemia (ALL): Results of the EWALL-INO Study

JAK Inhibition Mediates Clonal Selection of RAS Pathway Mutations in Myeloproliferative Neoplasms

Impact of NFE2 mutations on AML transformation and overall survival in patients with myeloproliferative neoplasms

Genomic Landscape and Clinical Features of Myeloproliferative Neoplasm (MPN) Patients with Auto-Immune and Inflammatory Diseases (AID)

Retrospective Analysis of the Outcomes of Patients with Relapsed/Refractory Acute Myeloid Leukemia Included in a Patient Named Program of Gemtuzumab Ozogamicin

The Omission of High-Dose Cytarabine during Consolidation Therapy of Ph-Positive ALL Patients Treated with Nilotinib and Low-Intensity Chemotherapy Results in an Increased Risk of Relapses Despite Non-Inferior Levels of Late BCR-ABL1 MRD Response. First Results of the Randomized Graaph-2014 Study

Fractionated Inotuzumab Ozogamicin Combined with Low-Intensity Chemotherapy Provides Very Good Outcome in Older Patients with Newly Diagnosed CD22+ Philadelphia Chromosome-Negative B-Cell Precursor Acute Lymphoblastic Leukemia: First Results from the EWALL-INO Study

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only